RNA interference and personalized cancer therapy

Discovery Medicine

Volumn 15, Issue 81, 2013, Pages 101-110

  Rao, Donald D ^a   Wang, Zhaohui ^a   Senzer, Neil ^a,b,c,d   Nemunaitis, John ^a,b,c,d  

^a GRADALIS INC   (United States)

^b Mary Crowley Cancer Research Centers   (United States)

^c TEXAS ONCOLOGY   (United States)

^d MEDICAL CITY DALLAS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); HUMAN; NEOPLASM; PERSONALIZED MEDICINE; RNA INTERFERENCE;

CLINICAL TRIALS AS TOPIC; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; RNA INTERFERENCE;

EID: 84882253822     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Albert R, Jeong H, Barabasi AL. Error and attack tolerance of complex networks. Nature 406(6794):378-382, 2000.
2. Aleku M, Schulz P, Keil O, Santel A, Schaeper U, Dieckhoff B, Janke O, Endruschat J, Durieux B, Roder N, Loffler K, Lange C, Fechtner M, Mopert K, Fisch G, Dames S, Arnold W, Jochims K, Giese K, Wiedenmann B, et al. Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression. Cancer Res 68(23):9788-9798, 2008.
3. Aleman LM, Doench J, Sharp PA. Comparison of siRNA-induced off-target RNA and protein effects. RNA (New York) 13(3):385-395, 2007.
4. Alli E, Yang JM, Hait WN. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene 26(7):1003-1012, 2007.
5. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E, Manning S, Wani S, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491(7424):399-405, 2012.
6. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA, Jr, Marks JR, Dressman HK, West M, Nevins JR. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439(7074):353-357, 2006.
7. Brennan MD, Cheong R, Levchenko A. Systems biology. How information theory handles cell signaling and uncertainty. Science 338(6105):334-335, 2012.
8. Burnett JC, Rossi JJ. RNA-based therapeutics: current progress and future prospects. Chem Biol 19(1):60-71, 2012.
9. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, Mclaren S, Lin ML, Mcbride DJ, Varela I, Nik-Zainal SA, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Griffin CA, Burton J, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467(7319):1109-1113, 2010.
10. Carlson JM, Doyle J. Complexity and robustness. Proc Natl Acad Sci U S A 99(Suppl 1):2538-2545, 2002.
11. Cervantes A, Alsina M, Tabernero J, Infante JR, Lorusso P, Shapiro G, Paz-Ares LG, Falzone R, Hill J, Cehelsky J, White A, Toudjarska I, Bumcrot D, Meyers R, Hinkle G, Svrzikapa N, Sah DW, Vaishnaw A, Gollob J, Burris HA. Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement. J Clin Oncol 29(Suppl): abstr 3025, 2011.
12. Collazos A, Michael N, Whelan RD, Kelly G, Mellor H, Pang LC, Totty N, Parker PJ. Site recognition and substrate screens for PKN family proteins. Biochem J 438(3):535-543, 2011.
13. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464(7291):1067-1070, 2010.
14. Desai A, Mitchison TJ. Microtubule polymerization dynamics. Annu Rev Cell Develop Biol 13:83-117, 1997.
15. Drews J. Drug discovery: a historical perspective. Science 287(5460):1960-1964, 2000.
16. Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Develop Cell 18(6):884-901, 2010.
17. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411(6836):494-498, 2001.
18. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391(6669):806-811, 1998.
19. Floor SL, Dumont JE, Maenhaut C, Raspe E. Hallmarks of cancer: of all cancer cells, all the time? Trends Mol Med 18(9):509-515, 2012.
20. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1):57-70, 2000.
21. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5):646-674, 2011.
22. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH. Integrating genetic approaches into the discovery of anticancer drugs. Science 278(5340):1064-1068, 1997.
23. Iancu C, Mistry SJ, Arkin S, Wallenstein S, Atweh GF. Effects of stathmin inhibition on the mitotic spindle. J Cell Sci 114(Pt 5):909-916, 2001.
24. Ichim TE, Li M, Qian H, Popov IA, Rycerz K, Zheng X, White D, Zhong R, Min WP. RNA interference: a potent tool for gene-specific therapeutics. Am J Transplant 4(8):1227-1236, 2004.
25. Jeong H, Mason SP, Barabasi AL, Oltvai ZN. Lethality and centrality in protein networks. Nature 411(6833):41-42, 2001.
26. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321(5897):1801-1806, 2008.
27. Komarova NL, Wodarz D. Drug resistance in cancer: principles of emergence and prevention. Proc Natl Acad Sci U S A 102(27):9714-9719, 2005.
28. Kumar P, Phalon C, Pappen BO, Wallraven G, Yu Y, Norvell F, Jay CM, Wang Z, Rao DD, Nemunaitis J, Senzer N, Maples PB. Expression of GMCSF, TGFβ1, TGFβ2 and Correlation to FURIN Expression in Culture Supernatants from Pre- and Post-FANGTM Plasmid Transfected Autologous Tumor Cells (abstract 511). Mol Ther 20(supp 1):s197, 2012.
29. Lakka SS, Gondi CS, Yanamandra N, Olivero WC, Dinh DH, Gujrati M, Rao JS. Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 23(27):4681-4689, 2004.
30. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75(5):843-854, 1993.
31. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, Hammond SM, Joshua-Tor L, Hannon GJ. Argonaute2 is the catalytic engine of mammalian RNAi. Science 305(5689):1437-1441, 2004.
32. Mardis ER. Applying next-generation sequencing to pancreatic cancer treatment. Nat Rev Gastroenterol Hepatol 9(8):477-486, 2012.
33. Merl S, Wessely R. Anti-coxsackieviral efficacy of RNA interference is highly dependent on genomic target selection and emergence of escape mutants. Oligonucleotides 17(1):44-53, 2007.
34. Mistry SJ, Atweh GF. Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer. Mol Cancer Ther 5(12):3248-3257, 2006.
35. Mistry SJ, Bank A, Atweh GF. Targeting stathmin in prostate cancer. Mol Cancer Ther 4(12):1821-1829, 2005.
36. Mistry SJ, Benham CJ, Atweh GF. Development of ribozymes that target stathmin, a major regulator of the mitotic spindle. Antisense Nucleic Acid Drug Dev 11(1):41-49, 2001.
37. Mitchison T, Kirschner M. Dynamic instability of microtubule growth. Nature 312(5991):237-242, 1984.
38. Morozova O, Marra MA. From cytogenetics to next-generation sequencing technologies: advances in the detection of genome rearrangements in tumors. Biochem Cell Biol 86(2):81-91, 2008.
39. Ngo TT, Peng T, Liang XJ, Akeju O, Pastorino S, Zhang W, Kotliarov Y, Zenklusen JC, Fine HA, Maric D, Wen PY, De Girolami U, Black PM, Wu WW, Shen RF, Jeffries NO, Kang DW, Park JK. The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. J Natl Cancer Inst 99(8):639-652, 2007.
40. Patnaik A, Chiorean EG, Tolcher A, Papadopoulos K, Beeram M, Kee D, Waddell M, Gilles E, Buchbinder A. EZN-2968, a novel hypoxia-inducible factor-1α (HIF-1α) messenger ribonucleic acid (mRNA) antagonist: Results of a phase I, pharmacokinetic (PK), dose-escalation study of daily administration in patients (pts) with advanced malignancies. J Clin Oncol 27(Suppl):15s, abstr 2564, 2009.
41. Phalon C, Rao DD, Nemunaitis J. Potential use of RNA interference in cancer therapy. Expert Rev Mol Med 12:e26, 2010.
42. Pirollo KF, Rait A, Zhou Q, Zhang XQ, Zhou J, Kim CS, Benedict WF, Chang EH. Tumor-targeting nanocomplex delivery of novel tumor suppressor RB94 chemosensitizes bladder carcinoma cells in vitro and in vivo. Clin Cancer Res 14(7):2190-2198, 2008.
43. Pleasance ED, Stephens PJ, O'Meara S, Mcbride DJ, Meynert A, Jones D, Lin ML, Beare D, Lau KW, Greenman C, Varela I, Nik-Zainal S, Davies HR, Ordonez GR, Mudie LJ, Latimer C, Edkins S, Stebbings L, Chen L, Jia M, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463(7278):184-190, 2010.
44. Press WH, Teukolsky SA, Vetterling WT, Flannery BP. Numerical Recipes in C: The Art of Scientific Computing, Second Edition. Cambridge University Press, New York, NY, USA, 1992.
45. Rao DD, Maples PB, Senzer N, Kumar P, Wang Z, Pappen BO, Yu Y, Haddock C, Jay C, Phadke AP, Chen S, Kuhn J, Dylewski D, Scott S, Monsma D, Webb C, Tong A, Shanahan D, Nemunaitis J. Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference. Cancer Gene Ther 17(11):780-791, 2010.
46. Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev 61(9):746-759, 2009.
47. Rolle K, Nowak S, Wyszko E, Nowak M, Zukiel R, Piestrzeniewicz R, Gawronska I, Barciszewska MZ, Barciszewski J. Promising human brain tumors therapy with interference RNA intervention (iRNAi). Cancer Biol Ther 9(5):396-406, 2010.
48. Santel A, Aleku M, Roder N, Mopert K, Durieux B, Janke O, Keil O, Endruschat J, Dames S, Lange C, Eisermann M, Loffler K, Fechtner M, Fisch G, Vank C, Schaeper U, Giese K, Kaufmann J. Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models. Clin Cancer Res 16(22):5469-5480, 2010.
49. Senzer N, Barve M, Bedell C, Kuhn J, Beitsch P, Steckler R, Hebeler R, Magee MJ, Taylor W, Gogel BM, Kumar P, Maples PB, Nemunaitis J. Phase I Study of the "triad" Autologous (FANGTM) vaccine, incorporating bifunctional shRNAfurin and GMCSF Transgene Expression, in Advanced Cancer Patients (abstract 331). Mol Ther 20(Supp 1):s130, 2012a.
50. Senzer N, Barve M, Kuhn J, Melnyk A, Beitsch P, Lazar M, Lifshitz S, Magee M, Oh J, Mill SW, Bedell C, Higgs C, Kumar P, Yu Y, Norvell F, Phalon C, Taquet N, Rao DD, Wang Z, Jay CM, et al. Phase I Trial of "bi-shRNAi(furin)/GMCSF DNA/Autologous Tumor Cell" Vaccine (FANG) in Advanced Cancer. Mol Ther 20(3):679-686, 2012b.
51. Strumberg D, Schultheis B, Traugott U, Vank C, Santel A, Keil O, Giese K, Kaufmann J, Drevs J. Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int J Clin Pharmacol Ther 50(1):76-78, 2012.
52. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis GN. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol 15(7):647-652, 1997.
53. Tiemann K, Rossi JJ. RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med 1(3):142-151, 2009.
54. Verdine GL, Walensky LD. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin Cancer Res 13(24):7264-7270, 2007.
55. Wang R, Dong K, Lin F, Wang X, Gao P, Wei SH, Cheng SY, Zhang HZ. Inhibiting proliferation and enhancing chemosensitivity to taxanes in osteosarcoma cells by RNA interference-mediated downregulation of stathmin expression. Mol Med (Cambridge, Mass) 13(11-12):567-575, 2007.
56. Wang Z, Rao DD, Senzer N, Nemunaitis J. RNA interference and cancer therapy. Pharm Res 28(12):2983-2995, 2011.
57. Weinstein IB. Cancer. Addiction to oncogenes - the Achilles heel of cancer. Science 297(5578):63-64, 2002.
58. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467(7319):1114-1117, 2010.
59. Zhang HZ, Wang Y, Gao P, Lin F, Liu L, Yu B, Ren JH, Zhao H, Wang R. Silencing Stathmin Gene Expression by Survivin Promoter-Driven siRNA Vector to Reverse Malignant Phenotype of Tumor Cells. Cancer Biol Ther 5(11):1457-1461, 2006.